Skip to main content

Advertisement

Table 2 Patient safety data through week 9

From: Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis

  Placebo Indigo naturalis
Patients treated, n 8 16
Patients with >1 adverse event, n (%) 4 (50.0) 7 (44.0)
Average duration of follow-up (weeks) 9.14 9.13
Average exposure (weeks) 8.16 8.13
Common adverse events, n (%)
 Pruritus 1 (12.5) 4 (25.0)
 Rash 0 (0.0) 2 (12.5)
 Nasopharyngitis 0 (0.0) 2 (12.5)
 Abdominal distension 0 (0.0) 1 (6.3)
 Constipation 0 (0.0) 1 (6.3)
 Cough 0 (0.0) 1 (6.3)
 Dizziness 0 (0.0) 1 (6.3)
 Oropharyngeal pain 0 (0.0) 1 (6.3)
 Gout 1 (12.5) 0 (0.0)
 Allergies 1 (12.5) 0 (0.0)
 Pyrexia 1 (12.5) 0 (0.0)